NuCana plc

NuCana plc is working on some hypotheses about why its Phase II NuTide:323 study of NUC-3373 in colorectal cancer was unsuccessful, including prognostic factors in the study arm versus the control ar

Biopharmaceutical companies launched 42 initial public offerings in the US in 2017 versus 30 in 2016 as stock values rose. But biotechnology in general endured a rough fourth quarter, raising the ques

The share price of Edinburgh, UK-based NuCana plc rose sharply on NASDAQ on Oct. 2, the day the biotech closed its initial public offering that raised a hefty $114m (£75m). The Scottish biopharmaceu

The number of biopharmaceutical company initial public offerings in the US this year is just one away from the 2016 total of 30 drug developer IPOs – and with returns from newly public companies risin